Optiscan Receives $1.69m R&D Tax Refund
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Optiscan Imaging Limited has announced the receipt of a research and development tax refund from the Australian Federal Government, amounting to a significant sum for the fiscal year reported. This refund is part of the government's incentive program aimed at supporting eligible companies engaged in qualifying R&D activities. The CEO highlighted that this funding reinforces the company's position and supports ongoing investment in key R&D programs and clinical studies.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Optiscan Imaging Limited on 6ix
Story so far
Earlier from Optiscan Imaging
- Optiscan Submits InSpecta FDA Dossier
- Appendix 4D
- Quarterly Activities/Appendix 4C Cash Flow Report
- Optiscan Initiates Head & Neck Cancer Imaging Study
- Optiscan Partners with ACL to Advance Digital Pathology
Later from Optiscan Imaging
- Second Anniversary of Optiscan and Mayo Clinic Agreement
- Halfway Mark Reached in Optiscan Breast Cancer Study
- Optiscan Launches InSpecta Device for Veterinary Medicine
- Head and Neck Study Progressing Ahead of Schedule
- Optiscan Signs New Research Agreement for Breast Study
Follow Optiscan Imaging into a list and get an email when it puts out news.
Follow Optiscan Imaging